How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Cancer Research Centers', 'Hospital', 'Others Market
- By Institution Type: Comprehensive Cancer Centers, Specialized Oncology Hospitals, Academic Medical Centers, Community Hospitals, Research Institutes
- By Funding Source: Government-Funded Centers, Private Non-Profit Organizations, For-Profit Healthcare Providers, Philanthropic Foundations, Academic Institutions
- By Research Focus: Basic Cancer Biology, Translational Research, Clinical Trials, Epidemiological Studies, Cancer Prevention and Control
- By Service Offering: Diagnostic Services, Surgical Oncology, Radiation Oncology, Medical Oncology, Palliative Care
- By Patient Population: Adult Oncology, Pediatric Oncology, Geriatric Oncology, Rare Cancers, Hematologic Malignancies
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Comprehensive Cancer Centers leads By Institution Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 305 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.186 →
- 12 Company Profiles 15 players: SWOT & benchmarking p.194 →
Full report · locked preview
Everything inside the Cancer Research Centers', 'Hospital', 'Others Market report
A complete, evidence-based study - 12 chapters and 128 sections covering market size, segmentation across 5 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Institution Type 5
Funding Source 5
Research Focus 5
Service Offering 5
Patient Population 5
Companies profiled
MD Anderson Cancer Center
Memorial Sloan Kettering Cancer Center
Dana-Farber Cancer Institute
Mayo Clinic Cancer Center
Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Cleveland Clinic Taussig Cancer Institute
Dana-Farber/Brigham and Women's Cancer Center
Fred Hutchinson Cancer Research Center
University of Texas Southwestern Medical Center
Royal Marsden Hospital
Gustave Roussy Institute
National Cancer Center Japan
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →MD Anderson Cancer Center
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Memorial Sloan Kettering Cancer Center
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Dana-Farber Cancer Institute
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Mayo Clinic Cancer Center
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Johns Hopkins Sidney Kimmel Comprehensive Cancer Center
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Cleveland Clinic Taussig Cancer Institute
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Dana-Farber/Brigham and Women's Cancer Center
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Fred Hutchinson Cancer Research Center
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →University of Texas Southwestern Medical Center
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Royal Marsden Hospital
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Gustave Roussy Institute
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →National Cancer Center Japan
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Peter MacCallum Cancer Centre
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →City of Hope Comprehensive Cancer Center
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Princess Margaret Cancer Centre
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$11,012M by 2033 · 10.2% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Comprehensive Cancer Centers53.1
- Specialized Oncology Hospitals8.9
- Academic Medical Centers13.3
- Community Hospitals12.6
- Research Institutes12.2
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,666M → $3,836M · 11.0%
Europe$1,161M → $2,682M · 11.0%
Asia Pacific$1,060M → $2,338M · 10.4%
Latin America$656.1M → $1,523M · 11.1%
Middle East and Africa$504.7M → $1,161M · 11.0%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →10.202026
10.212027
10.212028
10.232029
10.242030
10.252031
10.272032
10.282033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- MD Anderson Cancer Center24.7
- Memorial Sloan Kettering Cancer Center11.7
- Dana-Farber Cancer Institute5.4
- Mayo Clinic Cancer Center14.0
- Johns Hopkins Sidney Kimmel Comprehensive Cancer Center10.4
- Cleveland Clinic Taussig Cancer Institute5.9
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Institution Type20.6%
Funding Source19.7%
Research Focus18.1%
Service Offering20.6%
Patient Population21.0%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America33.2
- Europe23.2
- Asia Pacific20.3
- Latin America13.2
- Middle East and Africa10.1
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| MD Anderson Cancer Center | 93 | 82 | 85 | 84 | 74 | 92 | 85 |
| Memorial Sloan Kettering Cancer Center | 89 | 73 | 78 | 79 | 90 | 88 | 83 |
| Dana-Farber Cancer Institute | 64 | 64 | 79 | 79 | 75 | 78 | 73 |
| Mayo Clinic Cancer Center | 77 | 80 | 73 | 79 | 60 | 80 | 75 |
| Johns Hopkins Sidney Kimmel Comprehensive Cancer Center | 75 | 70 | 52 | 60 | 67 | 63 | 65 |
| Cleveland Clinic Taussig Cancer Institute | 69 | 51 | 46 | 49 | 54 | 68 | 56 |
| Dana-Farber/Brigham and Women's Cancer Center | 58 | 64 | 66 | 48 | 56 | 51 | 57 |
| Fred Hutchinson Cancer Research Center | 50 | 48 | 35 | 52 | 55 | 58 | 50 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- MD Anderson Cancer Center
- Memorial Sloan Kettering Cancer Center
- Dana-Farber Cancer Institute
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| MD Anderson Cancer Center | ✓ | ✓ | ◐ | ✓ | ◐ | ◐ |
| Memorial Sloan Kettering Cancer Center | ✓ | ✓ | ✓ | ✓ | ✓ | ◐ |
| Dana-Farber Cancer Institute | − | ◐ | ◐ | ◐ | ✓ | ✓ |
| Mayo Clinic Cancer Center | ◐ | ✓ | ✓ | ✓ | − | ◐ |
| Johns Hopkins Sidney Kimmel Comprehensive Cancer Center | − | − | − | ◐ | ◐ | ◐ |
| Cleveland Clinic Taussig Cancer Institute | ◐ | ◐ | − | ◐ | − | ◐ |
| Dana-Farber/Brigham and Women's Cancer Center | − | − | ✓ | − | ◐ | ◐ |
| Fred Hutchinson Cancer Research Center | ◐ | − | − | ◐ | ◐ | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1MD Anderson Cancer Center85
2Memorial Sloan Kettering Cancer Center83
3Mayo Clinic Cancer Center75
4Dana-Farber Cancer Institute73
5Johns Hopkins Sidney Kimmel Comprehensive Cancer Center65
6Dana-Farber/Brigham and Women's Cancer Center57
7Cleveland Clinic Taussig Cancer Institute56
8Fred Hutchinson Cancer Research Center50
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
MD Anderson Cancer CenterMemorial Sloan Kettering Cancer Center
Challenger2
Strong scale, closing on the leaders.
Dana-Farber Cancer InstituteMayo Clinic Cancer Center
Contender2
Focused players with pockets of strength.
Johns Hopkins Sidney Kimmel Comprehensive Cancer CenterDana-Farber/Brigham and Women's Cancer Center
Niche2
Specialists in a single segment or region.
Cleveland Clinic Taussig Cancer InstituteFred Hutchinson Cancer Research Center
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Institution Type in North America, then scale across Cancer Research Centers', 'Hospital', 'Others Market — a $163M beachhead inside a $2.38B market.
Beachhead (SOM)$163Mobtainable near-term
Serviceable (SAM)$937Mreachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale6 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion86 fit
Comprehensive Cancer Centers
Best fit — highest urgency & budget in Institution Type.
Economic buyer78 fit
Specialized Oncology Hospitals
Strong fit — clear ROI and a fast path to value.
End user70 fit
Academic Medical Centers
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Institution Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Funding Source & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Research Focus
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales45%
Partner / channel27%
Digital / self-serve20%
Marketplaces8%
Positioning & messaging
§GTM 2 · p.194 →For Institution Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Cancer Research Centers', 'Hospital', 'Others Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified42%
Sales qualified24%
Evaluation14%
Closed-won5%
$11.4KCAC
$56KLTV
4.9:1LTV : CAC
< 4 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Cancer Research Centers', 'Hospital', 'Others Market is a durable-growth opportunity — $9.42B by 2033, compounding at 8.9%.
TAM · 2025$4.76Btoday
TAM · 2033$9.42Bforecast
CAGR8.9%2027–2033
Cumulative$61.7Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$9.42BTotal addressable market
SAM$3.51BServiceable available market
SOM$613MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →8.9% CAGR
Demand compounds through 2033, outpacing GDP across Institution Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Institution Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$9.42BLarge & growingTAM by 2033 at 8.9% CAGR
$3.51BServiceable nowreachable with today’s model
$613MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$7.35BBear5.8% CAGR
$9.42BBase8.9% CAGR
$12.1BBull11.8% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Funding Source optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Cancer Research Centers', 'Hospital', 'Others Market — a $954M market by 2033. Plan: grow share from 10.6% to 17.6%.
Market size · 2033$954Mtotal addressable
Market CAGR3.8%2027–2033
Target share17.6%from 10.6% today
Revenue ambition$168Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 10.6% | 17.6% | Behind |
| Revenue | $99M | $168M | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | Ahead |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | On track |
| Gross margin | 32.4% | 41.6% | On track |
| Customer retention | 90.3% | 95.7% | At risk |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Institution Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Funding Source capability
A defensible second engine — invest in Funding Source to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Institution Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Funding Source
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $23M capacity & capability investment
- Greenlight bolt-on M&A in Funding Source
- Authorise North America expansion plan
- Fund R&D program for Institution Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownOn track
- Competitive share lossOn track
- Input-cost & supply riskAt risk
- Regulatory / policy changeOn track
- Execution & talentAhead
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Cancer Research Centers', 'Hospital', 'Others Market conversation — a $3.20B market you can size, segment and defend in minutes.
Market size · 2033$3.20Btotal opportunity
Growth8.9%CAGR to 2033
Addressable buyers1,602+accounts in scope
Typical ROI5.5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Institution Type
Goal Grow share in Institution Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →5.5×return on cost, year one
< 2 mopayback period
$80K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
MD Anderson Cancer CenterMemorial Sloan Kettering Cancer CenterDana-Farber Cancer InstituteMayo Clinic Cancer CenterJohns Hopkins Sidney Kimmel Comprehensive Cancer CenterCleveland Clinic Taussig Cancer InstituteDana-Farber/Brigham and Women's Cancer CenterFred Hutchinson Cancer Research Center+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Cancer Research Centers', 'Hospital', 'Others Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Cancer Research Centers', 'Hospital', 'Others Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Cancer Supportive Care Drug Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportCancer Therapeutics And Biotherapeutic Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportCancer Therapeutics Market
Market size, share, segmentation and regional forecast.
$6.3B market · 2025 base year
View reportCancer Therapy Market
Market size, share, segmentation and regional forecast.
$4.8B market · 2025 base year
View reportCancer Treatment Equipment Market
Market size, share, segmentation and regional forecast.
$4.4B market · 2025 base year
View reportCancer Treatment Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportCancer Treatments Market
Market size, share, segmentation and regional forecast.
$404M market · 2025 base year
View reportCancer Vaccines Drug Market
Market size, share, segmentation and regional forecast.
$3.4B market · 2025 base year
View reportCancer/Oncology Drugs Market
Market size, share, segmentation and regional forecast.
$1.2B market · 2025 base year
View reportCandesartan Cilexetil Market
Market size, share, segmentation and regional forecast.
$2.6B market · 2025 base year
View reportCandidate Relationship Management (CRM) Market
Market size, share, segmentation and regional forecast.
$2.8B market · 2025 base year
View reportCandidiasis Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.